NetworkNewsBreaks – Odyssey Health Inc. (ODYY) A
Post# of 85
(Total Views: 197)
Posted On: 08/18/2022 4:56:04 PM
NetworkNewsBreaks – Odyssey Health Inc. (ODYY) Achieves Positive Safety Outcomes for Concussion Drug in Multiple Ascending Dosing Trial
Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a company focused on developing unique, life-saving medical products including a novel compound for the treatment of concussion, has completed safety measures for its phase I multiday ascending dosing (“MAD”) clinical trial. According to the announcement, the trial is designed to study PRV-002, the company’s proprietary drug to treat concussion; this phase involves healthy human subjects. The company noted that the MAD cohort I, which was conducted at Nucleus Network, a leading clinical research organization, indicated the drug was safe and well tolerated. That phase involved eight healthy human volunteers who received either one dose of PRV-002 or placebo for five consecutive days; participants were then evaluated for abnormal responses. According to a Grandview Research report, the global market for concussion treatment has been projected to $8.9 billion by 2027. “After reviewing the data from MAD cohort I, I have strong confidence that PRV-002 will continue to show safety during the final, high-dose MAD portion of the phase I clinical trial,” said safety review committee member Dallas Hack, MD, in the press release. “We have unanimously approved the start of MAD Cohort II. The overall low levels of PRV-002 in the blood support the hypothesis that more drug is getting to the brain itself when administered with the intranasal device. If this turns out to be the case not only can the targeted effects of the drug be more efficacious, but the drug will also likely have fewer potential side effects.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a company focused on developing unique, life-saving medical products including a novel compound for the treatment of concussion, has completed safety measures for its phase I multiday ascending dosing (“MAD”) clinical trial. According to the announcement, the trial is designed to study PRV-002, the company’s proprietary drug to treat concussion; this phase involves healthy human subjects. The company noted that the MAD cohort I, which was conducted at Nucleus Network, a leading clinical research organization, indicated the drug was safe and well tolerated. That phase involved eight healthy human volunteers who received either one dose of PRV-002 or placebo for five consecutive days; participants were then evaluated for abnormal responses. According to a Grandview Research report, the global market for concussion treatment has been projected to $8.9 billion by 2027. “After reviewing the data from MAD cohort I, I have strong confidence that PRV-002 will continue to show safety during the final, high-dose MAD portion of the phase I clinical trial,” said safety review committee member Dallas Hack, MD, in the press release. “We have unanimously approved the start of MAD Cohort II. The overall low levels of PRV-002 in the blood support the hypothesis that more drug is getting to the brain itself when administered with the intranasal device. If this turns out to be the case not only can the targeted effects of the drug be more efficacious, but the drug will also likely have fewer potential side effects.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)